PL2766040T3 - Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi - Google Patents

Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi

Info

Publication number: PL2766040T3
Authority: PL; Poland
Prior art keywords: pertuzumab; trastuzumab; docetaxel; carboplatin; early
Prior art date: 2011-10-14

Application number

PL12778010T

Other languages

English (en)

Inventor

Sreedhara Alavattam

Lukas C Amler

Mark C Benyunes

Emma L Clark

Toledo Pelizon Christina H De

Glover Zephania W Kwong

Lada Mitchell

Jayantha Ratnayake

Graham A Ross

Ru-Amir Walker

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-14

Filing date

2012-10-11

Publication date

2019-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47073543&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2766040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-10-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2019-11-29 Publication of PL2766040T3 publication Critical patent/PL2766040T3/pl

Links

206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
190000008236 carboplatin Chemical compound 0.000 title 1
229960004562 carboplatin Drugs 0.000 title 1
229960003668 docetaxel Drugs 0.000 title 1
229960002087 pertuzumab Drugs 0.000 title 1
229960000575 trastuzumab Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Packages (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

PL12778010T 2011-10-14 2012-10-11 Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi PL2766040T3 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201161547535P	2011-10-14	2011-10-14
US201161567015P	2011-12-05	2011-12-05
US201261657669P	2012-06-08	2012-06-08
US201261682037P	2012-08-10	2012-08-10
US201261694584P	2012-08-29	2012-08-29
PCT/US2012/059683 WO2013055874A2 (en)	2011-10-14	2012-10-11	Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
EP12778010.4A EP2766040B1 (en)	2011-10-14	2012-10-11	Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer

Publications (1)

Publication Number	Publication Date
PL2766040T3 true PL2766040T3 (pl)	2019-11-29

Family

ID=47073543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12778010T PL2766040T3 (pl)	2011-10-14	2012-10-11	Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi

Country Status (29)

Country	Link
US (9)	US20130095172A1 (pl)
EP (5)	EP4234034A3 (pl)
JP (8)	JP2014530235A (pl)
KR (4)	KR20230028585A (pl)
CN (8)	CN116271013A (pl)
AU (4)	AU2012322797B2 (pl)
BR (1)	BR112014007521A8 (pl)
CL (1)	CL2014000889A1 (pl)
DK (1)	DK2766040T3 (pl)
EA (1)	EA034390B1 (pl)
ES (1)	ES2736005T3 (pl)
HK (1)	HK1202242A1 (pl)
HR (1)	HRP20191247T1 (pl)
HU (1)	HUE044352T2 (pl)
IL (4)	IL301603A (pl)
IN (1)	IN2014CN02703A (pl)
LT (1)	LT2766040T (pl)
MX (2)	MX2014004021A (pl)
MY (2)	MY194408A (pl)
PE (1)	PE20142363A1 (pl)
PH (1)	PH12019500519A1 (pl)
PL (1)	PL2766040T3 (pl)
PT (1)	PT2766040T (pl)
RS (1)	RS58944B1 (pl)
SG (3)	SG10201606756PA (pl)
SI (1)	SI2766040T1 (pl)
UA (2)	UA123092C2 (pl)
WO (1)	WO2013055874A2 (pl)
ZA (1)	ZA201401259B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
ES2440481T3 (es)	2005-02-23	2014-01-29	Genentech, Inc.	Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
CL2008000614A1 (es)	2007-03-02	2008-09-05	Genentech Inc F Hoffmann La Ro	Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
US9901567B2 (en)	2007-08-01	2018-02-27	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
PT2344478T (pt)	2008-11-03	2017-11-28	Syntarga Bv	Análogos de cc-1065 e seus conjugados
DK3056203T3 (da)	2010-04-21	2018-01-29	Syntarga Bv	Konjugater af cc-1065-analoger og bifunktionelle linkere.
IL301603A (en)	2011-10-14	2023-05-01	Genentech Inc	Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US9180185B2 (en)	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
SG10201911353WA (en)	2013-04-16	2020-02-27	Genentech Inc	Pertuzumab variants and evaluation thereof
SG11201509508YA (en) *	2013-06-19	2015-12-30	Seragon Pharmaceuticals Inc	Estrogen receptor modulator and uses thereof
BR112016013896A2 (pt)	2013-12-17	2017-10-10	Genentech Inc	métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
CN104726462A (zh) *	2013-12-20	2015-06-24	北京天广实生物技术股份有限公司	抗her2人源化抗体mil41、其制备方法及用途
PL3092010T3 (pl)	2014-01-10	2019-01-31	Synthon Biopharmaceuticals B.V.	Sposób oczyszczania połączonych cysteiną koniugatów przeciwciało-lek
SG11201605597VA (en) *	2014-01-10	2016-08-30	Synthon Biopharmaceuticals Bv	Duocarmycin adcs for use in treatment of endometrial cancer
CN105899236B (zh) *	2014-01-10	2019-07-26	斯索恩生物制药有限公司	表现出改进的体内抗肿瘤活性的倍癌霉素adc
WO2016094341A1 (en) *	2014-12-08	2016-06-16	Synta Pharmaceuticals Corp.	Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer
EP3304072A4 (en) *	2015-05-29	2018-12-05	Expression Pathology, Inc.	Quantifying her2 protein for optimal cancer therapy
CA2986263A1 (en)	2015-06-17	2016-12-22	Genentech, Inc.	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
MA45324A (fr)	2016-03-15	2019-01-23	Seattle Genetics Inc	Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
CA3040913A1 (en) *	2016-11-04	2018-05-11	Genentech, Inc.	Treatment of her2-positive breast cancer
JP6914336B2 (ja) *	2016-12-28	2021-08-04	ジェネンテック，インコーポレイテッド	進行したｈｅｒ２発現がんの治療
PT3570884T (pt) *	2017-01-17	2020-11-24	Hoffmann La Roche	Formulações subcutâneas de anticorpo do her2
CN116531511A (zh)	2017-03-02	2023-08-04	豪夫迈·罗氏有限公司	Her2阳性乳腺癌的辅助治疗
WO2020080892A1 (ko) *	2018-10-19	2020-04-23	주식회사 프로티나	Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
EA202193257A1 (ru) *	2019-05-27	2022-03-10	Толмар Интернэшнл Лимитед	Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы
KR20220027969A (ko)	2019-06-28	2022-03-08	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	프리리포솜 아나마이신 동결건조물의 제조
MX2021015667A (es) *	2019-06-28	2022-04-18	Univ Texas	Metodo de reconstitucion de anamicina liposomica.
WO2021222068A1 (en) *	2020-04-29	2021-11-04	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment
CN111710425A (zh) *	2020-06-19	2020-09-25	复旦大学附属中山医院	一种免疫检查点抑制剂心脏毒性评估方法，***及装置
US11896558B2 (en) *	2021-12-07	2024-02-13	Io Therapeutics, Inc.	Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0171407B1 (en)	1984-01-30	1993-11-18	Imperial Cancer Research Technology Limited	Improvements relating to growth factors
US5401638A (en)	1986-06-04	1995-03-28	Oncogene Science, Inc.	Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en)	1986-12-31	1990-11-06	The Regents Of The University Of California	Determination of status in neoplastic disease
US5720937A (en)	1988-01-12	1998-02-24	Genentech, Inc.	In vivo tumor detection assay
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE69031120T2 (de)	1989-05-19	1998-01-15	Genentech Inc	Her2 extrazellulare domäne
WO1991005264A1 (en)	1989-09-29	1991-04-18	Oncogenetics Partners	Detection and quantification of neu related proteins in the biological fluids of humans
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
WO1993006217A1 (en)	1991-09-19	1993-04-01	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2435462T3 (es)	1995-07-27	2013-12-19	Genentech, Inc.	Formulación de proteína liofilizada isotónica estable
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US7371376B1 (en)	1996-10-18	2008-05-13	Genentech, Inc.	Anti-ErbB2 antibodies
EP0852951A1 (de)	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ATE371673T1 (de)	1996-11-27	2007-09-15	Genentech Inc	Affinitätsreinigung von polypeptiden an einer protein a-matrix
US5994071A (en)	1997-04-04	1999-11-30	Albany Medical College	Assessment of prostate cancer
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
ES2308836T3 (es)	1998-03-27	2008-12-01	Genentech, Inc.	Sinergia de los anticuerpos anti-her-2 y de los ligands para l'apo-2.
AU760048B2 (en) *	1998-05-06	2003-05-08	Genentech Inc.	Protein purification by ion exchange chromatography
US6573043B1 (en)	1998-10-07	2003-06-03	Genentech, Inc.	Tissue analysis and kits therefor
EP1187632B1 (en)	1999-05-14	2008-12-03	Genentech, Inc.	TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20030086924A1 (en)	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ES2282120T3 (es)	1999-06-25	2007-10-16	Genentech, Inc.	Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
US20040013667A1 (en)	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
CN101121021B (zh)	1999-06-25	2011-12-07	杰南技术公司	人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
CA2382100A1 (en)	1999-08-27	2001-03-08	Genentech, Inc.	Dosages for treatment with anti-erbb2 antibodies
US6632979B2 (en)	2000-03-16	2003-10-14	Genentech, Inc.	Rodent HER2 tumor model
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
KR101135233B1 (ko)	2000-05-19	2012-04-12	제넨테크, 인크.	ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
US6984494B2 (en)	2000-08-15	2006-01-10	Genentech, Inc.	Analytical method
EP2325205A3 (en)	2000-12-28	2011-10-12	Altus Pharmaceuticals Inc.	Crystals of whole antibodies and fragments thereof and methods for making and using them
EP2289942B1 (en)	2002-04-10	2013-07-31	Genentech, Inc.	Anti-HER2 antibody variants
US20050276812A1 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Antibody-drug conjugates and methods
PL214010B1 (pl)	2002-07-15	2013-06-28	Genentech Inc	Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
ES2629602T5 (es)	2002-09-11	2021-06-08	Genentech Inc	Purificación de proteínas
WO2004030621A2 (en) *	2002-09-30	2004-04-15	The Trustees Of Boston University	Method of treating cancer using adenosine and its analogs
WO2004048525A2 (en)	2002-11-21	2004-06-10	Genentech, Inc.	Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP3722309A1 (en)	2003-07-28	2020-10-14	Genentech, Inc.	Reducing protein a leaching during protein a affinity chromatography
US20060034840A1 (en)	2004-04-08	2006-02-16	Agus David B	ErbB antagonists for pain therapy
SV2006002143A (es)	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20050280299A1 (en)	2004-06-18	2005-12-22	Alfmeier Corporation	Mounting adaptor for seat assembly, and seat assembly having mounting adaptor
UA90480C2 (uk)	2004-07-22	2010-05-11	Джэнэнтэк, Инк.	Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
AU2005285347A1 (en)	2004-08-19	2006-03-23	Genentech, Inc.	Polypeptide variants with altered effector function
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
WO2006048749A1 (en) *	2004-11-04	2006-05-11	Pfizer Products Inc.	Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
JP2008523073A (ja)	2004-12-07	2008-07-03	ジェネンテック・インコーポレーテッド	Ｈｅｒ阻害剤を用いた治療のための患者の選択
CN101141981A (zh)	2005-01-21	2008-03-12	健泰科生物技术公司	Her抗体的固定剂量给药
DK2301531T3 (en) *	2005-02-18	2018-07-30	Abraxis Bioscience Llc	COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY
ES2440481T3 (es)	2005-02-23	2014-01-29	Genentech, Inc.	Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
WO2006096861A2 (en)	2005-03-08	2006-09-14	Genentech, Inc.	METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en)	2005-03-14	2006-09-21	Genentech, Inc.	Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en)	2005-07-06	2007-01-11	Helmut Lenz	Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es)	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en)	2005-08-12	2010-04-20	Hoffmann-La Roche Inc.	Method for predicting the response to a treatment
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2035039A2 (en) *	2006-06-05	2009-03-18	Genentech, Inc.	Extending survival of cancer patients with elevated levels of egf or tgf-alpha
EP2045010B1 (en)	2006-06-14	2011-09-21	Cataler Corporation	Exhaust gas purifying catalyst
US20080050385A1 (en)	2006-08-21	2008-02-28	Thomas Friess	Tumor therapy with an anti-vegf antibody
WO2008031531A1 (en) *	2006-09-15	2008-03-20	F. Hoffmann-La Roche Ag	Tumor therapy with a combination of anti-her2 antibodies
CL2008000614A1 (es)	2007-03-02	2008-09-05	Genentech Inc F Hoffmann La Ro	Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
ES2555784T3 (es)	2007-06-06	2016-01-08	F. Hoffmann-La Roche Ag	Composición de un primer anticuerpo monoclonal no marcado, que se une a un antígeno de tumor y un segundo anticuerpo monoclonal que no tiene reacción cruzada y está marcado con un marcador de fluorescencia NIR
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl)	2007-06-08	2013-07-31	Genentech, Inc.	Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
EP2205242B1 (en)	2007-09-12	2015-04-15	Genentech, Inc.	Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009051815A1 (en) *	2007-10-19	2009-04-23	Bipar Sciences, Inc.	Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
US20090148435A1 (en)	2007-10-30	2009-06-11	Genentech, Inc.	Antibody purification by cation exchange chromatography
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090203015A1 (en) *	2008-02-13	2009-08-13	Celera Corporation	Multiplex assays for hormonal and growth factor receptors, and uses thereof
JP2011513432A (ja)	2008-03-06	2011-04-28	ジェネンテック，インコーポレイテッド	ｃ−ｍｅｔ及びＨＥＲアンタゴニストの併用療法
AR070865A1 (es)	2008-03-18	2010-05-12	Genentech Inc	Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
CA2744158A1 (en) *	2008-11-22	2010-05-27	Genentech, Inc.	Anti-angiogenesis therapy for the treatment of breast cancer
SG10201507044PA (en)	2009-05-29	2015-10-29	Hoffmann La Roche	Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
AR079256A1 (es) *	2009-12-04	2012-01-04	Genentech Inc	Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
IL301603A (en)	2011-10-14	2023-05-01	Genentech Inc	Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient

2012
- 2012-10-11 IL IL301603A patent/IL301603A/en unknown
- 2012-10-11 EP EP23172860.1A patent/EP4234034A3/en active Pending
- 2012-10-11 CN CN202310108240.2A patent/CN116271013A/zh active Pending
- 2012-10-11 HU HUE12778010 patent/HUE044352T2/hu unknown
- 2012-10-11 EP EP23172847.8A patent/EP4241849A3/en active Pending
- 2012-10-11 WO PCT/US2012/059683 patent/WO2013055874A2/en active Application Filing
- 2012-10-11 KR KR1020237005562A patent/KR20230028585A/ko not_active Application Discontinuation
- 2012-10-11 EA EA201490779A patent/EA034390B1/ru active Protection Beyond IP Right Term
- 2012-10-11 PE PE2014000507A patent/PE20142363A1/es active IP Right Grant
- 2012-10-11 EP EP12778010.4A patent/EP2766040B1/en not_active Revoked
- 2012-10-11 MY MYPI2019003795A patent/MY194408A/en unknown
- 2012-10-11 CN CN202310064889.9A patent/CN116271011B/zh active Active
- 2012-10-11 IN IN2703CHN2014 patent/IN2014CN02703A/en unknown
- 2012-10-11 SG SG10201606756PA patent/SG10201606756PA/en unknown
- 2012-10-11 US US13/649,591 patent/US20130095172A1/en not_active Abandoned
- 2012-10-11 CN CN202210486683.0A patent/CN114984205A/zh active Pending
- 2012-10-11 BR BR112014007521A patent/BR112014007521A8/pt not_active Application Discontinuation
- 2012-10-11 MX MX2014004021A patent/MX2014004021A/es active IP Right Grant
- 2012-10-11 CN CN201811518146.XA patent/CN109908341B/zh active Active
- 2012-10-11 PT PT12778010T patent/PT2766040T/pt unknown
- 2012-10-11 RS RS20190845A patent/RS58944B1/sr unknown
- 2012-10-11 SG SG10202110077Q patent/SG10202110077QA/en unknown
- 2012-10-11 DK DK12778010.4T patent/DK2766040T3/da active
- 2012-10-11 IL IL309917A patent/IL309917A/en unknown
- 2012-10-11 EP EP23172794.2A patent/EP4234033A3/en active Pending
- 2012-10-11 CN CN201280061896.3A patent/CN104334189A/zh active Pending
- 2012-10-11 ES ES12778010T patent/ES2736005T3/es active Active
- 2012-10-11 CN CN202310701159.5A patent/CN116808199A/zh active Pending
- 2012-10-11 SG SG11201401432XA patent/SG11201401432XA/en unknown
- 2012-10-11 KR KR1020237015216A patent/KR20230073340A/ko active Application Filing
- 2012-10-11 AU AU2012322797A patent/AU2012322797B2/en active Active
- 2012-10-11 KR KR1020147009738A patent/KR102099991B1/ko active IP Right Grant
- 2012-10-11 MY MYPI2014001060A patent/MY172326A/en unknown
- 2012-10-11 JP JP2014535859A patent/JP2014530235A/ja not_active Withdrawn
- 2012-10-11 CN CN202310135044.4A patent/CN116236569A/zh active Pending
- 2012-10-11 LT LTEP12778010.4T patent/LT2766040T/lt unknown
- 2012-10-11 CN CN202310820523.XA patent/CN117018187A/zh active Pending
- 2012-10-11 EP EP19165341.9A patent/EP3598981A3/en not_active Withdrawn
- 2012-10-11 PL PL12778010T patent/PL2766040T3/pl unknown
- 2012-10-11 KR KR1020177004681A patent/KR102502545B1/ko active IP Right Grant
- 2012-10-11 UA UAA201709999A patent/UA123092C2/uk unknown
- 2012-10-11 SI SI201231637T patent/SI2766040T1/sl unknown
- 2012-11-10 UA UAA201405091A patent/UA116095C2/uk unknown
2014
- 2014-02-19 ZA ZA2014/01259A patent/ZA201401259B/en unknown
- 2014-03-06 IL IL231350A patent/IL231350B2/en unknown
- 2014-04-03 MX MX2019009153A patent/MX2019009153A/es unknown
- 2014-04-09 CL CL2014000889A patent/CL2014000889A1/es unknown
2015
- 2015-03-17 HK HK15102729.7A patent/HK1202242A1/xx unknown
2016
- 2016-03-02 US US15/058,520 patent/US20160175438A1/en not_active Abandoned
- 2016-07-15 AU AU2016204962A patent/AU2016204962B2/en active Active
2017
- 2017-06-28 JP JP2017125883A patent/JP2017222663A/ja not_active Withdrawn
2018
- 2018-06-05 AU AU2018203970A patent/AU2018203970B2/en active Active
- 2018-09-06 US US16/123,809 patent/US20190117769A1/en not_active Abandoned
2019
- 2019-03-11 PH PH12019500519A patent/PH12019500519A1/en unknown
- 2019-07-11 HR HRP20191247TT patent/HRP20191247T1/hr unknown
- 2019-10-02 JP JP2019182187A patent/JP6646785B1/ja active Active
- 2019-11-04 AU AU2019261666A patent/AU2019261666B2/en active Active
2020
- 2020-01-10 JP JP2020002531A patent/JP2020090507A/ja not_active Withdrawn
- 2020-02-20 US US16/796,163 patent/US20200206348A1/en not_active Abandoned
- 2020-08-13 US US16/992,966 patent/US20210015919A1/en not_active Abandoned
- 2020-08-17 US US16/994,950 patent/US20200376120A1/en not_active Abandoned
2021
- 2021-10-03 IL IL286921A patent/IL286921A/en unknown
2022
- 2022-01-06 JP JP2022000876A patent/JP2022062010A/ja not_active Withdrawn
- 2022-03-28 US US17/656,732 patent/US20220362379A1/en active Pending
2023
- 2023-04-28 US US18/309,488 patent/US20230277664A1/en active Pending
- 2023-04-28 US US18/309,452 patent/US20230277663A1/en active Pending
- 2023-05-01 JP JP2023075391A patent/JP7352760B2/ja active Active
- 2023-05-01 JP JP2023075388A patent/JP7303957B1/ja active Active
- 2023-09-15 JP JP2023150231A patent/JP2024009803A/ja active Pending

Also Published As

Publication number	Publication date
HUE044352T2 (hu)	2019-10-28
US20200376120A1 (en)	2020-12-03
IL309917A (en)	2024-03-01
EP3598981A3 (en)	2020-06-10
CL2014000889A1 (es)	2014-07-25
US20160175438A1 (en)	2016-06-23
ZA201401259B (en)	2019-01-30
ES2736005T3 (es)	2019-12-23
US20210015919A1 (en)	2021-01-21
AU2016204962B2 (en)	2018-03-08
MY194408A (en)	2022-11-30
AU2018203970B2 (en)	2019-11-21
CN104334189A (zh)	2015-02-04
EP4234033A3 (en)	2023-09-20
CN114984205A (zh)	2022-09-02
IL231350B2 (en)	2023-08-01
CN117018187A (zh)	2023-11-10
EP4234033A2 (en)	2023-08-30
PH12019500519A1 (en)	2021-06-14
BR112014007521A2 (pt)	2017-12-12
MY172326A (en)	2019-11-21
SI2766040T1 (sl)	2019-08-30
JP2020090507A (ja)	2020-06-11
DK2766040T3 (da)	2019-07-22
US20200206348A1 (en)	2020-07-02
US20190117769A1 (en)	2019-04-25
CN116271013A (zh)	2023-06-23
HK1202242A1 (en)	2015-09-25
PT2766040T (pt)	2019-07-11
EP2766040A2 (en)	2014-08-20
WO2013055874A3 (en)	2013-06-20
KR102502545B1 (ko)	2023-02-21
US20130095172A1 (en)	2013-04-18
KR20170023195A (ko)	2017-03-02
KR20230073340A (ko)	2023-05-25
BR112014007521A8 (pt)	2018-04-10
EP4234034A2 (en)	2023-08-30
JP2023109780A (ja)	2023-08-08
RS58944B1 (sr)	2019-08-30
AU2019261666A1 (en)	2019-11-28
JP2017222663A (ja)	2017-12-21
EA034390B1 (ru)	2020-02-03
LT2766040T (lt)	2019-08-12
AU2018203970A1 (en)	2018-06-21
EP3598981A2 (en)	2020-01-29
NZ750877A (en)	2020-09-25
EP4234034A3 (en)	2023-09-20
CN116808199A (zh)	2023-09-29
AU2012322797B2 (en)	2016-04-21
SG10202110077QA (en)	2021-10-28
HRP20191247T1 (hr)	2019-10-18
JP7352760B2 (ja)	2023-09-28
SG11201401432XA (en)	2014-05-29
CN109908341A (zh)	2019-06-21
EP4241849A2 (en)	2023-09-13
NZ621367A (en)	2016-04-29
CN116271011B (zh)	2023-10-27
PE20142363A1 (es)	2015-01-30
MX2014004021A (es)	2014-04-30
JP2023109779A (ja)	2023-08-08
IL231350A0 (en)	2014-04-30
IL301603A (en)	2023-05-01
JP2024009803A (ja)	2024-01-23
EP2766040B1 (en)	2019-05-15
CN116271011A (zh)	2023-06-23
KR20230028585A (ko)	2023-02-28
KR20140075725A (ko)	2014-06-19
AU2016204962A1 (en)	2016-08-04
CN109908341B (zh)	2023-06-27
US20230277663A1 (en)	2023-09-07
CN116236569A (zh)	2023-06-09
JP2022062010A (ja)	2022-04-19
UA116095C2 (uk)	2018-02-12
JP6646785B1 (ja)	2020-02-14
US20220362379A1 (en)	2022-11-17
AU2019261666B2 (en)	2021-08-05
EA201490779A1 (ru)	2015-11-30
JP2014530235A (ja)	2014-11-17
SG10201606756PA (en)	2016-10-28
AU2012322797A8 (en)	2014-06-26
JP7303957B1 (ja)	2023-07-05
UA123092C2 (uk)	2021-02-17
WO2013055874A2 (en)	2013-04-18
IL231350B1 (en)	2023-04-01
JP2020033353A (ja)	2020-03-05
MX2019009153A (es)	2019-10-14
EP4241849A3 (en)	2023-09-20
KR102099991B1 (ko)	2020-04-14
IL286921A (en)	2021-10-31
AU2012322797A1 (en)	2014-03-20
US20230277664A1 (en)	2023-09-07
IN2014CN02703A (pl)	2015-07-03

Publication	Publication Date	Title
PL2766040T3 (pl)	2019-11-29	Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
IL276434A (en)	2020-09-30	Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL279330A (en)	2021-01-31	Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL237558A0 (en)	2015-04-30	Methods for treating locally advanced breast cancer
HK1254859A1 (zh)	2019-07-26	治療乳腺癌的方法
EP2744830A4 (en)	2015-06-17	ANTI-LSR ANTIBODIES AND THEIR USES FOR THE TREATMENT OF CANCER
HK1199290A1 (en)	2015-06-26	Methods and compositions for the treatment and diagnosis of breast cancer
ME02932B (me)	2018-04-20	Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
EP2755679A4 (en)	2015-09-30	IMMUNOGENS INDUCING CYTOTOXIC T LYMPHOCYTES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER